A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis

AGMB-447 · שלב 2

מזהה רישום
NCT07862634
שלב
שלב 2
סטטוס
טרם החל גיוס
תרופה / התערבות
AGMB-447
ממן
Agomab Spain S.L.U.
מספר משתתפים
120

על הניסוי

The main goal of this clinical trial is to find out if an experimental inhaled drug, AGMB-447, can help improve lung function in people living with a lung disease called idiopathic pulmonary fibrosis (IPF). To do this, the effects of the study drug will be compared to a placebo, which is a treatment that looks like the study drug but contains no active medicine. The specific goals of the trial are as follows: Primary Objective and Estimand: The main goal is to see if 24 weeks of treatment with AGMB-447 helps the lungs work better than a placebo. This is measured by checking the total amount of air a person can forcefully blow out after taking a deep breath. The study will measure this effect for all participants who start the trial, regardless of whether they are able to finish the full

צפו ב-NCT07862634 ב-ClinicalTrials.gov ←

ניסויים קשורים

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT07862634 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.